Medical Condition News

RSS

AGA conference highlights emerging technologies for digestive and metabolic disorders

The American Gastroenterological Association (AGA) is taking the lead in gastroenterological innovation by conducting "Fostering Innovation and Technology in Digestive and Metabolic Diseases."

24 Feb 2010

Catalyst Pharmaceutical Partners, NIDA partner to conduct CPP-109 Phase II(b) clinical trial for cocaine addiction

Catalyst Pharmaceutical Partners, Inc. announced today that it has signed a non-binding Letter of Intent with the National Institute on Drug Abuse (NIDA) to conduct a U.S. Phase II(b) clinical trial evaluating CPP-109, Catalyst's formulation of vigabatrin, for the treatment of cocaine addiction. It is anticipated that NIDA, under their agreement with Veteran's Administration Cooperative Studies Program, will provide substantial resources for the trial and that Catalyst will contribute approximately $2.5 million in resources as part of the estimated $10 million trial cost.

23 Feb 2010

Findings suggest bitter melon extract may help in preventing breast cancer

Bitter melon extract, a common dietary supplement, exerts a significant effect against breast cancer cell growth and may eventually become a chemopreventive agent against this form of cancer, according to results of a recent study.

23 Feb 2010

FDA Gastrointestinal Drugs Advisory Committee supports approval of XIFAXAN 550 mg for management of HE

Salix Pharmaceuticals, Ltd. today reported that the Gastrointestinal Drugs Advisory Committee of the FDA has recommended by a vote of 14 to 4 in favor of the approval of XIFAXAN® (rifaximin) Tablets, 550 mg for the maintenance of remission of hepatic encephalopathy (HE).

23 Feb 2010

Timely treatment and rehabilitation key to proper healing

Sometimes athletes can be their own worst enemy especially when they continue to play following an injury to a foot or ankle. Surgeons presenting at the Annual Scientific Conference of the American College of Foot and Ankle Surgeons (ACFAS) today are discussing athletic injuries and the importance of proper diagnosis, prompt treatment, and full healing and rehabilitation.

23 Feb 2010

Elevated cerebrospinal fluid levels of P-tau231 may be an early diagnostic biomarker for Alzheimer's disease

Researchers at NYU School of Medicine have found that elevated cerebrospinal fluid levels of phosphorylated tau231 (P-tau231), a damaged tau protein found in patients with Alzheimer's disease, may be an early diagnostic biomarker for Alzheimer's disease in healthy adults.

23 Feb 2010

Cephalon to acquire Ception Therapeutics following positive clinical study of eosinophilic asthma

Cephalon, Inc. (Nasdaq: CEPH) announced today that it has exercised its option to acquire Ception Therapeutics, Inc., following receipt of positive data from a clinical study in adults with eosinophilic asthma.

23 Feb 2010

New Barts Cancer Research UK Centre launched

A new cancer centre, launched today, puts London at the forefront of cancer research.

23 Feb 2010

NASDAQ halts trading of Salix Pharmaceuticals stock, FDA Committee to discuss XIFAXAN NDA

Salix Pharmaceuticals, Ltd. today announced that NASDAQ has halted trading of the Company’s common stock this morning. The Gastrointestinal Drugs Advisory Committee of the FDA is meeting today to discuss the efficacy and safety of the New Drug Application (NDA) for XIFAXAN® (rifaximin) Tablets, 550 mg for the maintenance of remission of hepatic encephalopathy.

23 Feb 2010

Study proves accuracy of MTWA non-invasive test in identifying patients at risk of arrhythmic events and SCD

Cambridge Heart, Inc., today announced that results of a clinical study presented at the 29th Annual Scientific Meeting of the Belgian Society of Cardiology in Brussels, Belgium, reinforce the value of the Microvolt T-wave Alternans (MTWA) as an accurate non-invasive test to identify patients at risk of arrhythmic events and sudden cardiac death (SCD).

23 Feb 2010

Lexicon Pharmaceuticals reports positive results from Phase 2 clinical trials for IBS and type 2 diabetes

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three months and year ended December 31, 2009.

23 Feb 2010

NCC, Pfizer provide over 10M units of ReFacto Antihemophilic Factor to underserved hemophilia patients

The National Cancer Coalition (NCC) is pleased to announce its recent collaboration with Pfizer, Inc to provide hemophilia medicines to underserved patients in the developing world. To date, NCC has received more than 10 million international units of ReFacto® Antihemophilic Factor (Recombinant), a therapy used for the treatment and prevention of bleeding in people with hemophilia A, to assist patients who otherwise would have little opportunity for adequate treatment. The value of this donation is more than $13 million, and it will help many hundreds of hemophilia patients around the world.

23 Feb 2010

Gross sales of Acorda Therapeutics' ZANAFLEX CAPSULES and tablets increase 9.1% to $58.3M in 2009

Acorda Therapeutics, Inc. today announced its financial results for the fourth quarter and full year ended December 31, 2009.

23 Feb 2010

Simple test to check personal cholesterol levels

CardioChek® test system is used by Americans and people in 100 countries around the world to test personal cholesterol levels. Simple, reliable and fast, CardioChek is manufactured by Indianapolis company Polymer Technology Systems, Inc., a leading global provider of point-of-care diagnostic products to the healthcare industry. On February 15th the CardioChek test system was featured on Lifetime Channel’s program, “The Balancing Act,” and will air again on February 22nd and March 15th.

23 Feb 2010

NewCardio's CardioBip technology for remote wireless monitoring demonstrates reliable detection of AF

NewCardio, Inc., a cardiac diagnostic technology provider, announced today that the Heart Rhythm Society (HRS) has accepted an abstract detailing the superior performance of NewCardio's patented CardioBip™ technology for remote wireless monitoring and detection of atrial fibrillation (AF). The study results, which discuss the use of CardioBip for improved AF monitoring and detection, are scheduled for oral presentation at the Heart Rhythm Society 31st Annual Scientific Sessions, May 12-15, 2010, in Denver, Colorado.

23 Feb 2010

Key mechanism that makes brain cells become tumorous identified

Researchers from the Peninsula Medical School in Plymouth (UK), the Memorial Sloan-Kettering Cancer Center in New York, Cornell University in New York, Weil Medical College in New York and the Center for Neural Tumour Research in Los Angeles, have for the first time identified a key mechanism that makes certain cells become tumorous in the brain. The resulting tumours occur most often spontaneously but can also occur in numbers as part of the inherited disease Neurofibromatosis type 2.

23 Feb 2010

DNA interval in unexplored region of human genome increases risk for coronary artery disease

Scientists from the U.S. Department of Energy's Lawrence Berkeley National Laboratory have learned how an interval of DNA in an unexplored region of the human genome increases the risk for coronary artery disease, the leading cause of death worldwide.

23 Feb 2010

Slightly to moderately elevated CRP levels in patients undergoing CABG surgery: Implications

A new study published in the March issue of Anesthesiology raises awareness for an additional risk category for patients undergoing routine coronary artery bypass surgery - low to moderate levels of inflammation.

23 Feb 2010

Genentech's Avastin combination Phase III study in advanced stomach cancer does not meet primary endpoint

Genentech, Inc., a wholly owned member of the Roche Group, today announced that a Phase III study (AVAGAST) did not meet its primary endpoint of showing Avastin® (bevacizumab) plus Xeloda® (capecitabine) or 5-FU and cisplatin chemotherapy extended the lives of people with inoperable or advanced stomach (gastric) cancer, compared to chemotherapy alone.

23 Feb 2010

FDA issues approval for Gileads's Cayston for respiratory symptoms in cystic fibrosis

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Cayston® (aztreonam for inhalation solution) as a treatment to improve respiratory symptoms in cystic fibrosis patients with Pseudomonas aeruginosa. Cayston’s safety and efficacy have not been established in pediatric patients below the age of 7, patients with forced expiratory volume in one second of less than 25 percent or greater than 75 percent predicted, or patients colonized with Burkholderia cepacia.

23 Feb 2010

Medical Condition News

AGA conference highlights emerging technologies for digestive and metabolic disorders

Catalyst Pharmaceutical Partners, NIDA partner to conduct CPP-109 Phase II(b) clinical trial for cocaine addiction

Findings suggest bitter melon extract may help in preventing breast cancer

FDA Gastrointestinal Drugs Advisory Committee supports approval of XIFAXAN 550 mg for management of HE

Timely treatment and rehabilitation key to proper healing

Elevated cerebrospinal fluid levels of P-tau231 may be an early diagnostic biomarker for Alzheimer's disease

Cephalon to acquire Ception Therapeutics following positive clinical study of eosinophilic asthma

New Barts Cancer Research UK Centre launched

NASDAQ halts trading of Salix Pharmaceuticals stock, FDA Committee to discuss XIFAXAN NDA

Study proves accuracy of MTWA non-invasive test in identifying patients at risk of arrhythmic events and SCD

Lexicon Pharmaceuticals reports positive results from Phase 2 clinical trials for IBS and type 2 diabetes

NCC, Pfizer provide over 10M units of ReFacto Antihemophilic Factor to underserved hemophilia patients

Gross sales of Acorda Therapeutics' ZANAFLEX CAPSULES and tablets increase 9.1% to $58.3M in 2009

Simple test to check personal cholesterol levels

NewCardio's CardioBip technology for remote wireless monitoring demonstrates reliable detection of AF

Key mechanism that makes brain cells become tumorous identified

DNA interval in unexplored region of human genome increases risk for coronary artery disease

Slightly to moderately elevated CRP levels in patients undergoing CABG surgery: Implications

Genentech's Avastin combination Phase III study in advanced stomach cancer does not meet primary endpoint

FDA issues approval for Gileads's Cayston for respiratory symptoms in cystic fibrosis

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News